key: cord-1032853-pihf23s4
authors: Capuano, Rocco; Donnarumma, Giovanna; Bisecco, Alvino; Grimaldi, Elena; Conte, Miriana; d’Ambrosio, Alessandro; Matrone, Federica; Risi, Mario; Borgo, Riccardo Maria; Altieri, Manuela; Giuliano, Federica; Coppola, Nicola; Galdiero, Massimiliano; Tedeschi, Gioacchino; Gallo, Antonio
title: Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
date: 2021-08-13
journal: Ther Adv Neurol Disord
DOI: 10.1177/17562864211038111
sha: d8596c4007c8d95dac3bf8f5bf6f533c15404c84
doc_id: 1032853
cord_uid: pihf23s4

nan

Since the worldwide launch of the SARS-CoV-2 vaccine campaign, there have been many uncertainties regarding the immune response to vaccination in patients with multiple sclerosis (pwMS), particularly those on high-efficacy disease-modifying therapies (DMTs). 1 Achiron and colleagues 2 for the first time investigated the short-term humoral response to COVID-19 mRNA vaccine in pwMS treated with high-efficacy DMTs, in particular ocrelizumab (OCR), fingolimod (FNG), and cladribine (CLD). The study results showed that pwMS on OCR and FNG have a blunted humoral response to mRNA vaccine; contrariwise, CLD-treated pwMS have an efficient humoral response. The study from Achiron and colleagues did not focus on the humoral response to BNT162b2 mRNA Covid-19 vaccine in pwMS treated with natalizumab (NTZ), another high-efficacy DMT largely used in multiple sclerosis (MS). NTZ binds to α4β1-integrin, inhibiting leukocyte migration into the central nervous system and thus reducing the MS-related inflammatory activity. 3 Since studies on humoral response to vaccines in NTZ-treated pwMS reported contrasting results, 4-8 two recent consensus have stated that there are no sufficient data to draw any definitive and generalizable conclusion regarding the efficacy of vaccines during treatment with NTZ. 9,10 Therefore, it is of paramount importance to assess the response to SARS-CoV-2 vaccines in NTZ-treated pwMS, especially in the presence of new vaccine platforms. On this background, we decided to investigate the humoral response to BNT162b2 mRNA Covid-19 vaccine in pwMS treated with NTZ and to compare it to age-and sex-matched healthy controls (HCs).

We collected serum samples before the first dose and 7 days after the second dose of the BNT162b2 mRNA Covid-19 vaccine from HCs and pwMS on NTZ with: (1) no history of Covid-19, (2) no positive SARS-CoV-2 IgG antibodies at baseline, (3) no steroid administration within the month before the first dose of vaccine. Sera were tested at virology laboratory of our University Hospital, using the LIAISON® SARS-CoV-2 TrimericS-IgG assay (DiaSorin-S.p.A.), for the detection of IgG antibodies to SARS-CoV-2 spike protein, including neutralizing antibodies. 11 The IgG titers were expressed in binding antibody units (BAU), with 33.8 BAU/mL as negative/positive cut-off. 12 The local Ethics Committee (named 'Comitato Etico Università degli Studi della Campania Luigi Vanvitelli -Azienda Ospedaliera Universitaria Luigi Vanvitelli -AORN Ospedali dei Colli') approved the study that was performed in accordance with the principles of Helsinki Declaration (approval code: 0015914).

Statistical analysis was performed with Stata version 14.0 (StataCorp, College Station, TX).

Mild to moderate vaccine adverse reactions were commonly reported in HCs and pwMS, with rates expected in general population; 13 no serious or unexpected local and systemic side effects were observed in both groups. We did not observe post-vaccination MS worsening or relapses within 1 month after the second dose administration. As for similar studies, the main limitations of this study were (1) the lack of assessment of the cellmediated immune response, known to be essential in vaccine immunogenicity, and (2) the short-term follow-up.

In conclusion, this is the first report on the immunogenicity of BNT162b2 mRNA Covid-19 vaccine in pwMS treated with NTZ and integrates the study by Achiron and colleagues on OCR, FNG, and CLD. 2 Our findings indicate that BNT162b2 mRNA Covid-19 vaccine in patients treated with NTZ is safe and yields a short-term humoral immune response comparable to that achieved in HCs, independent of demographic, clinical, and drugrelated variables.

Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic: implications on the risk of infection and future vaccination

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

Humoral immune response to influenza vaccine in natalizumab-treated MS patients

Immunogenicity and predictors of response to a diseasemodifying therapies

Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Vaccinations in patients with multiple sclerosis: a Delphi consensus statement

Practice guideline update summary: vaccinepreventable infections and immunization in multiple sclerosis: report of the guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

TrimericS IgG assay for the detection of circulating antibodies

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients

The authors thank Gabriella Andreone, Salvatore Abbadessa, Carolina Vitulano, and Pasquale Sozio for helping in data acquisition and analysis.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The authors received no financial support for the research, authorship, and/or publication of this article.

Rocco Capuano https://orcid.org/0000-0003-4889-8182